1. Home
  2. WINT vs ISPC Comparison

WINT vs ISPC Comparison

Compare WINT & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • ISPC
  • Stock Information
  • Founded
  • WINT 1992
  • ISPC 2009
  • Country
  • WINT United States
  • ISPC United States
  • Employees
  • WINT N/A
  • ISPC N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • ISPC Precision Instruments
  • Sector
  • WINT Health Care
  • ISPC Health Care
  • Exchange
  • WINT Nasdaq
  • ISPC Nasdaq
  • Market Cap
  • WINT 3.6M
  • ISPC 3.2M
  • IPO Year
  • WINT 1995
  • ISPC 2021
  • Fundamental
  • Price
  • WINT $0.83
  • ISPC $1.13
  • Analyst Decision
  • WINT Hold
  • ISPC
  • Analyst Count
  • WINT 1
  • ISPC 0
  • Target Price
  • WINT $350.00
  • ISPC N/A
  • AVG Volume (30 Days)
  • WINT 224.2K
  • ISPC 41.6K
  • Earning Date
  • WINT 05-16-2025
  • ISPC 05-27-2025
  • Dividend Yield
  • WINT N/A
  • ISPC N/A
  • EPS Growth
  • WINT N/A
  • ISPC N/A
  • EPS
  • WINT N/A
  • ISPC N/A
  • Revenue
  • WINT N/A
  • ISPC $9,291,115.00
  • Revenue This Year
  • WINT N/A
  • ISPC $35.93
  • Revenue Next Year
  • WINT N/A
  • ISPC N/A
  • P/E Ratio
  • WINT N/A
  • ISPC N/A
  • Revenue Growth
  • WINT N/A
  • ISPC N/A
  • 52 Week Low
  • WINT $1.01
  • ISPC $1.02
  • 52 Week High
  • WINT $737.50
  • ISPC $11.80
  • Technical
  • Relative Strength Index (RSI)
  • WINT 29.36
  • ISPC 42.26
  • Support Level
  • WINT $0.81
  • ISPC $1.09
  • Resistance Level
  • WINT $0.95
  • ISPC $1.25
  • Average True Range (ATR)
  • WINT 0.09
  • ISPC 0.08
  • MACD
  • WINT 0.04
  • ISPC 0.00
  • Stochastic Oscillator
  • WINT 6.14
  • ISPC 12.50

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Share on Social Networks: